Canaglu approved by MHLW (Japan) for treatment of chronic kidney disease complicated by type 2 diabetes. - Mitsubishi Tanabe
Mitsubishi Tanabe Pharma Corporation has approval for partial changes to Canaglu (canagliflozin) tablets 100 mg for the additional indication of chronic kidney disease complicated with type 2 diabetes mellitus ( excluding patients with end stage renal disease) or undergoing dialysis.
Type 2 diabetes mellitus is a major risk factor for the development and progression of chronic kidney disease (CKD)and CKD complicated with type 2 diabetes is very common.in such patients renal function decreases as the disease progresses but if renal failure develops., dialysis needs to be started. Dialysis not only reduces a patients quality of life but also is an important issue from the viewpoint of health economics. The approval of Canaglu will provide one option to resolve these issues and contribute to the quality of life.
Related news and insights
Roche announced that the FDA has approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumours have activating HER2 (ERBB2) mutations, as detected by a FDA-approved test, and who have received a prior systemic therapy
The Menarini Group announced that the FDA has accepted the Company’s New Drug Application (NDA) for elacestrant, an investigational selective estrogen receptor degrader (SERD), for patients with ER+/HER2- advanced or metastatic breast cancer.